CTAD 2025 | Results from the Phase IIb trial of neflamapimod in dementia with Lewy bodies

James Galvin, MD, MPH, Miller School of Medicine, Miami, FL, discusses results from the Phase IIb study of neflamapimod in the treatment of dementia with Lewy bodies. He highlights that although the initial randomized double-blind placebo-controlled study was negative, the open-label extension showed a treatment effect when sufficient plasma levels were reached. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.